Skip to content
FindTrial
Search trials
Search trials by condition, treatment, sponsor...
Sign In
Recombinant Human Papillomavirus Nonavalent (Types 6,11,16,18,31,33,45,52,58 )Vaccine(E.Coli)
BIOLOGICAL
2 trials
Sponsors
Xiamen University
Conditions
Cervical Cancer
Condylomata Acuminata
Phase 3
Immunogenicity of a Recombinant Human Papillomavirus Nonavalent (Types 6,11,16,18,31,33,45,52,58)Vaccine(E.Coli) Versus Gardasil®9 in Healthy Females 18-26 Years of Age
Completed
NCT04782895
Xiamen University
Cervical Cancer, Condylomata Acuminata
Start: 2021-03-14
End: 2022-07-25
Updated: 2023-06-15
Unknown Phase
Plateau Antibody Levels of a Recombinant (E.Coli) HPV Nonavalent Vaccine Versus Gardasil®9 in Young Women
Active, not recruiting
NCT06197802
Xiamen University
Cervical Cancer, Condylomata Acuminata
Start: 2023-12-30
End: 2025-09-01
Target: 392
Updated: 2025-07-31
Related Papers
Immunogenicity comparison of an <i>Escherichia coli</i>-produced 9-valent human papillomavirus vaccine and Gardasil9 in Chinese women aged 18-26 years: three-year follow-up data from a randomised clinical trial.
2025-08-27
Head-to-head immunogenicity comparison of an Escherichia coli-produced 9-valent human papillomavirus vaccine and Gardasil 9 in women aged 18-26 years in China: a randomised blinded clinical trial.
2023-07-17
28 citations